BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23143190)

  • 1. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
    Chen C; Wang FH; An X; Luo HY; Wang ZQ; Liang Y; Zhang L; Li YH
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):371-8. PubMed ID: 23143190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
    Wang Y; Wang ZQ; Jiang YX; Wang FH; Luo HY; Liang Y; Wang DS; Li YH
    Expert Opin Pharmacother; 2016 Aug; 17(12):1585-90. PubMed ID: 27328125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
    Kua VF; Ismail F; Chee Ee Phua V; Aslan NM
    Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
    McCarthy JS; Tannock IF; Degendorfer P; Panzarella T; Furlan M; Siu LL
    Oral Oncol; 2002 Oct; 38(7):686-90. PubMed ID: 12167421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.
    Gao Y; Huang HQ; Bai B; Cai QC; Wang XX; Cai QQ
    Expert Opin Pharmacother; 2014 Feb; 15(2):163-71. PubMed ID: 24295173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
    Hasbini A; Mahjoubi R; Fandi A; Chouaki N; Taamma A; Lianes P; Cortès-Funes H; Alonso S; Armand JP; Cvitkovic E; Raymond E
    Ann Oncol; 1999 Apr; 10(4):421-5. PubMed ID: 10370784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
    Xue C; Huang Y; Huang PY; Yu QT; Pan JJ; Liu LZ; Song XQ; Lin SJ; Wu JX; Zhang JW; Zhao HY; Xu F; Liu JL; Hu ZH; Zhao LP; Zhao YY; Wu X; Zhang J; Ma YX; Zhang L
    Ann Oncol; 2013 Apr; 24(4):1055-61. PubMed ID: 23172635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Taamma A; Fandi A; Azli N; Wibault P; Chouaki N; Hasbini A; Couteau C; Armand JP; Cvitkovic E
    Cancer; 1999 Oct; 86(7):1101-8. PubMed ID: 10506692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
    Huang HQ; Cai QQ; Lin XB; Wang AL; Bu Q; Hu XH; Pan ZH; Li YH; Shuang YR; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):314-6. PubMed ID: 18788641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    Hong S; Zhang Y; Yu G; Peng P; Peng J; Jia J; Wu X; Huang Y; Yang Y; Lin Q; Xi X; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C; Fang W; Zhang L
    J Clin Oncol; 2021 Oct; 39(29):3273-3282. PubMed ID: 34379443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
    Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
    Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
    Zhou J; Zhang WM; Chen H; Xie B; Zheng JH; Xu ZY; Lin JR
    Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):867-72. PubMed ID: 20137355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
    Huang HQ; Zhou ZM; Li YH; Jiang WQ; He YJ; Teng XY; Guan ZZ
    Ai Zheng; 2002 Apr; 21(4):409-11. PubMed ID: 12452022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.